NorthWest Biotherapeutics Inc (NWBO)

[JFR161162]

Thanks StonkMaster.

With respect, I think you are wrong in your daily genetic projections regarding the approval timeline in the UK.
I think you underestimate the importance of the political agenda in a pre-election year and the importance of DCVAX approval for future research into new therapies.
Since the UK is no longer part of the EU (Brexit 2020), the credit given to medical research has fallen to a critical level.
This poses a huge risk for the country, as it could be slow in bringing new therapies to its citizens.
Additionally, the country ranks among the worst in brain cancer survival among 29 comparable countries.

All this leads me to say that following the extraordinary results of Ph III (best results in 17 years for nGBM and best results in 27 years for rGBM), no toxicity and data available for more than 10 years in the compassionate program , DCVAX will be approved very soon, at the latest in May, perhaps as early as April, before the general election is called.

Politicians are already salivating at the prospect of taking credit for this major discovery in cancer treatment and the possibility of putting the UK on the map as THE world leader in cell therapies.